{"organizations": [], "uuid": "549489a4aec1cad7b87d6add1bee73aa63c80c74", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-inventiva-fy-operating-loss-widens/brief-inventiva-fy-operating-loss-widens-to-20-9-million-euros-idUSFWN1QP0T0", "country": "US", "domain_rank": 408, "title": "BRIEF-Inventiva FY Operating Loss Widens to 20.9 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-03-08T01:20:00.000+02:00", "replies_count": 0, "uuid": "549489a4aec1cad7b87d6add1bee73aa63c80c74"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-inventiva-fy-operating-loss-widens/brief-inventiva-fy-operating-loss-widens-to-20-9-million-euros-idUSFWN1QP0T0", "ord_in_thread": 0, "title": "BRIEF-Inventiva FY Operating Loss Widens to 20.9 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Inventiva Sa:\n* FY OPERATING LOSS EUR 20.9 MILLION VERSUS EUR 13.0 MILLION YEAR AGO‍​\n* FY REVENUE EUR 6.5 MILLION VERSUS EUR 9.4 MILLION YEAR AGO‍​\n* CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL INSTRUMENTS AMOUNTED TO €59 MILLION AT DECEMBER 31, 2017\n* FY NET LOSS EUR 17.2 MILLION VERSUS EUR 7.0 MILLION YEAR AGO‍​\n* ‍CLINICAL DEVELOPMENT OF NEW DRUG CANDIDATE, ABBV-157, IS EXPECTED TO BEGIN IN 2018​\n* PARTNERSHIP WITH ABBVIE AND BOEHRINGER INGELHEIM IS ADVANCING ON SCHEDULE\n* ‍TOPLINE RESULTS OF PHASE IIB FASST TRIAL ARE EXPECTED ON SCHEDULE AT BEGINNING OF 2019​\n* CLINICAL DEVELOPMENT OF NEW DRUG CANDIDATE, ABBV-157, EXPECTED TO BEGIN IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T01:20:00.000+02:00", "crawled": "2018-03-08T17:33:46.012+02:00", "highlightTitle": ""}